S
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SSE:688505
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SSE:688505
Price:
7.73 CNY
0.39%
Market Closed
Updated:
May 4, 2024
Income Statement
Earnings Waterfall
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
|
Revenue
|
850.7m
CNY
|
|
Cost of Revenue
|
-74.1m
CNY
|
|
Gross Profit
|
776.7m
CNY
|
|
Operating Expenses
|
-674.3m
CNY
|
|
Operating Income
|
102.3m
CNY
|
|
Other Expenses
|
6.3m
CNY
|
|
Net Income
|
108.6m
CNY
|
Income Statement
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Revenue |
496
N/A
|
834
+68%
|
925
+11%
|
997
+8%
|
1 036
+4%
|
1 140
+10%
|
1 155
+1%
|
1 013
-12%
|
1 158
+14%
|
1 031
-11%
|
1 080
+5%
|
1 283
+19%
|
1 023
-20%
|
851
-17%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(39)
|
(64)
|
(69)
|
(74)
|
(79)
|
(81)
|
(91)
|
(90)
|
(93)
|
(86)
|
(97)
|
(104)
|
(91)
|
(74)
|
|
| Gross Profit |
457
N/A
|
770
+68%
|
856
+11%
|
923
+8%
|
957
+4%
|
1 059
+11%
|
1 064
+0%
|
922
-13%
|
1 065
+16%
|
945
-11%
|
982
+4%
|
1 179
+20%
|
932
-21%
|
777
-17%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(383)
|
(619)
|
(686)
|
(737)
|
(780)
|
(869)
|
(875)
|
(858)
|
(953)
|
(820)
|
(853)
|
(927)
|
(750)
|
(674)
|
|
| Selling, General & Administrative |
(294)
|
(472)
|
(532)
|
(556)
|
(587)
|
(643)
|
(669)
|
(650)
|
(732)
|
(581)
|
(630)
|
(694)
|
(539)
|
(436)
|
|
| Research & Development |
(102)
|
(129)
|
(167)
|
(183)
|
(196)
|
(212)
|
(227)
|
(229)
|
(237)
|
(214)
|
(233)
|
(242)
|
(223)
|
(226)
|
|
| Depreciation & Amortization |
0
|
(32)
|
0
|
0
|
0
|
(35)
|
0
|
0
|
0
|
(36)
|
0
|
0
|
0
|
(39)
|
|
| Other Operating Expenses |
13
|
15
|
14
|
3
|
4
|
22
|
22
|
21
|
16
|
10
|
9
|
9
|
13
|
25
|
|
| Operating Income |
75
N/A
|
151
+102%
|
171
+13%
|
186
+9%
|
177
-5%
|
191
+8%
|
190
0%
|
64
-66%
|
112
+74%
|
124
+11%
|
129
+4%
|
251
+95%
|
182
-28%
|
102
-44%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
10
|
18
|
21
|
23
|
19
|
25
|
21
|
22
|
18
|
8
|
7
|
3
|
3
|
(1)
|
|
| Non-Reccuring Items |
4
|
4
|
7
|
4
|
5
|
1
|
2
|
2
|
2
|
1
|
2
|
3
|
2
|
(5)
|
|
| Total Other Income |
1
|
4
|
3
|
2
|
2
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(2)
|
(0)
|
(0)
|
1
|
|
| Pre-Tax Income |
89
N/A
|
177
+99%
|
201
+14%
|
216
+7%
|
203
-6%
|
216
+7%
|
212
-2%
|
88
-58%
|
132
+50%
|
132
+1%
|
137
+3%
|
257
+88%
|
186
-28%
|
98
-48%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(4)
|
(12)
|
(14)
|
(16)
|
(5)
|
(4)
|
0
|
23
|
(0)
|
5
|
5
|
(15)
|
4
|
11
|
|
| Income from Continuing Operations |
85
|
164
|
188
|
200
|
197
|
212
|
212
|
111
|
131
|
137
|
141
|
242
|
190
|
108
|
|
| Income to Minority Interest |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
|
| Net Income (Common) |
85
N/A
|
165
+94%
|
188
+14%
|
201
+7%
|
198
-1%
|
213
+8%
|
213
0%
|
112
-48%
|
132
+18%
|
138
+5%
|
142
+3%
|
242
+71%
|
191
-21%
|
109
-43%
|
|
| EPS (Diluted) |
0.08
N/A
|
0.17
+113%
|
0.18
+6%
|
0.19
+6%
|
0.19
N/A
|
0.2
+5%
|
0.2
N/A
|
0.11
-45%
|
0.18
+64%
|
0.13
-28%
|
0.13
N/A
|
0.24
+85%
|
0.19
-21%
|
0.11
-42%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
